Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI study of SP2086 and Valsartan in healthy volunteers
NCT02815657Phase 1Completed
- Sponsor
- Hengrui
- Start
- Apr 2013
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of retagliptin in type 2 diabetes mellitus (T2DM), sponsored by Hengrui. Primary endpoint: Maximum plasma concentration of SP2086 at Day 31. Started Apr 2013; status: completed.
02
Drugs
retagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02815657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02815657.